Related Experiment Video
Updated: Sep 14, 2025
Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
Published on: September 13, 2019
SMU-pRMS: a novel cell line of pleomorphic rhabdomyosarcoma
Naoya Nakahashi1, Makoto Emori2, Yasutaka Murahashi1
1Department of Orthopaedic Surgery, Sapporo Medical University School of Medicine, West 16, South 1, Chuo- Ku, Sapporo, 060-8543, Japan.
Abstract:
Pleomorphic rhabdomyosarcoma (pRMS) is a rare and highly malignant mesenchymal tumor. Complete resection is the only curative treatment available, owing to the limited efficacy of chemotherapy and radiotherapy. Therefore, developing novel therapies for pRMS is important for improving clinical outcomes. Herein, a novel pRMS cell line, SMU-pRMS, was established for a detailed understanding of the biological characteristics of pRMS, thereby developing new therapies. A tissue sample from a surgically resected tumor of a 69-year-old patient was subjected to primary culture. The cell line was established and authenticated by evaluating the short tandem repeats of DNA microsatellites. Monolayer cultures of SMU-pRMS cells exhibited constant growth, spheroid formation, and invasiveness. These cells exhibited high chemosensitivity to eribulin. In addition, mice inoculated with SMU-pRMS cells developed tumors after 4 weeks. Therefore, the SMU-pRMS cell line is a useful tool for investigating pRMS development and evaluating novel therapeutic agents.
Insights
A new cell line, SMU-pRMS, was developed for studying pleomorphic rhabdomyosarcoma (pRMS). This model shows promise for understanding pRMS and testing new treatments like eribulin.
Area of Science:
- Oncology
- Cell Biology
- Cancer Research
Background:
- Pleomorphic rhabdomyosarcoma (pRMS) is a rare, aggressive mesenchymal tumor.
- Current treatments have limited efficacy, necessitating novel therapeutic strategies.
- Complete surgical resection remains the primary curative option.
Purpose of the Study:
- Establish and characterize a novel pRMS cell line for research.
- Investigate the biological behavior and therapeutic sensitivity of pRMS.
- Provide a valuable tool for preclinical drug development.
Main Methods:
- Primary culture of tumor tissue from a patient with pRMS.
- Cell line establishment and authentication using DNA microsatellite analysis.
- In vitro characterization of cell growth, spheroid formation, and invasiveness.
- In vivo tumor development in mice and chemosensitivity testing.
Main Results:
- The SMU-pRMS cell line was successfully established and authenticated.
- SMU-pRMS cells demonstrated consistent growth, invasiveness, and spheroid formation.
- Significant chemosensitivity to eribulin was observed in vitro.
- Tumor formation occurred in mice inoculated with SMU-pRMS cells within 4 weeks.
Conclusions:
- The SMU-pRMS cell line serves as a robust preclinical model for pRMS research.
- This cell line facilitates the investigation of pRMS pathogenesis and the evaluation of novel therapeutic agents.
- SMU-pRMS offers a platform for advancing the development of effective pRMS treatments.
Related Concept Videos
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:16Cell Lines